A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have advanced, unresectable or metastatic cancer (solid tumors)
Participants Must Not:
Participant must not have known HIV infection or hepatitis A, B, or C
Participant must not have current blood cancers, acute or chronic leukemia
Participant must not have previously completed or withdrawn from this study or any other study investigating an ERK1/2 inhibitor - Female participant must not be pregnant, breastfeeding, or planning to become pregnant
Part C: have serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study, including interstitial lung disease (ILD) or severe dyspnea at rest or requiring oxygen therapy
Part C4 NRAS Melanoma: have previously completed or withdrawn from a study investigating a MEK inhibitor
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo